Company Description
Salspera is focused on the development and commercialization of a new class of immunotherapeutics for the treatment of solid tumors.
This new class of drugs, sometimes referred to as “live biopharmaceuticals” are genetically modified biological agents which have the capability of expressing select anti-tumoral agents within the tumor’s microenvironment.
Our lead program, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and orally administered.
Saltikva is being developed for the treatment of multiple oncology indications, including pancreatic cancer and osteosarcoma.
Our Company is entering into pivotal Phase 3 clinical trials for our Saltikva product in the treatment of Stage IV metastatic pancreatic cancer patients.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Eddie Moradian, PhD |
Contact Details
Address: 45 Prospect Street Cambridge, MA 02139 United States | |
| Phone | (652) 402-5587 |
| Website | salspera.com |
Stock Details
| Ticker Symbol | TKVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2084032 |
| Employer ID | 87-4698872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eddie Moradian | Executive Chairman, Chief Executive Officer, Chief Financial Officer and Director |
| Daniel Saltzman, MD | Chief Medical Officer and Director |
| Brent Lonson | Chief Financial Officer |
| Charles Garner | Director |
| Luisa Ingargiola | Director |
| David Schaffer, PhD | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 2, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 29, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 12, 2025 | DRS | [Cover] Draft Registration Statement |